US Stock MarketDetailed Quotes

Monte Rosa Therapeutics (GLUE)

Watchlist
  • 17.480
  • -0.570-3.16%
Close Apr 10 16:00 ET
  • 17.820
  • +0.340+1.95%
Post 16:51 ET
1.40BMarket Cap-38.00P/E (TTM)

Monte Rosa Therapeutics (GLUE) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
63.54%123.67M
-95.41%2.78M
38.54%12.77M
394.01%23.19M
7,882.05%84.93M
75.62M
60.65M
9.22M
4.7M
1.06M
Operating revenue
63.54%123.67M
-95.41%2.78M
38.54%12.77M
394.01%23.19M
7,882.05%84.93M
--75.62M
--60.65M
--9.22M
--4.7M
--1.06M
Cost of revenue
Gross profit
Operating expense
13.49%177.88M
10.19%52.5M
27.98%45.74M
3.78%38.75M
13.56%40.89M
9.37%156.73M
36.66%47.64M
-3.31%35.74M
0.31%37.34M
5.11%36.01M
Selling and administrative expenses
3.44%36.38M
19.82%10.52M
11.54%9.07M
-12.79%8.1M
-3.14%8.7M
9.78%35.17M
13.57%8.78M
-6.17%8.13M
13.96%9.28M
19.74%8.99M
-General and administrative expense
3.44%36.38M
19.82%10.52M
11.54%9.07M
-12.79%8.1M
-3.14%8.7M
9.78%35.17M
13.57%8.78M
-6.17%8.13M
13.96%9.28M
19.74%8.99M
Research and development costs
16.40%141.5M
8.01%41.98M
32.81%36.68M
9.26%30.65M
19.11%32.19M
9.25%121.56M
43.23%38.87M
-2.44%27.62M
-3.51%28.06M
1.01%27.03M
Operating profit
33.17%-54.21M
-482.31%-49.72M
-24.31%-32.98M
52.35%-15.55M
226.01%44.04M
43.40%-81.11M
137.30%13M
28.24%-26.53M
12.30%-32.64M
-2.01%-34.95M
Net non-operating interest income expense
22.49%12.94M
42.16%3.69M
-5.05%2.75M
16.34%3.07M
40.83%3.44M
13.20%10.57M
9.59%2.6M
29.86%2.89M
14.55%2.64M
0.21%2.44M
Non-operating interest income
22.49%12.94M
42.16%3.69M
-5.05%2.75M
16.34%3.07M
40.83%3.44M
13.20%10.57M
9.59%2.6M
29.86%2.89M
14.55%2.64M
0.21%2.44M
Other net income (expense)
270.91%1.54M
-2,600.00%-50K
81.05%-29K
2,722.64%1.39M
-62.58%232K
140.12%416K
100.26%2K
-666.67%-153K
23.19%-53K
387.04%620K
Gain on sale of security
256.73%1.48M
-2,600.00%-50K
81.05%-29K
2,722.64%1.39M
-72.10%173K
139.21%416K
100.26%2K
-666.67%-153K
43.01%-53K
387.04%620K
Special income (charges)
--59K
--0
--0
--0
--59K
--0
--0
--0
--0
--0
-Gain on sale of property,plant,equipment
--59K
--0
--0
--0
--59K
--0
--0
--0
--0
--0
Income before tax
43.36%-39.72M
-395.34%-46.08M
-27.20%-30.26M
63.08%-11.1M
249.62%47.71M
48.06%-70.13M
146.89%15.6M
31.47%-23.79M
14.09%-30.06M
0.48%-31.89M
Income tax
-142.68%-1.1M
-97.27%59K
-4,574.65%-3.18M
375.79%1.2M
890.36%822K
660.36%2.57M
9,936.36%2.16M
-58.24%71K
32.63%252K
83K
Net income
46.87%-38.63M
-443.34%-46.14M
-13.50%-27.08M
59.44%-12.3M
246.66%46.89M
46.29%-72.7M
140.41%13.44M
31.60%-23.86M
13.84%-30.31M
0.22%-31.97M
Net income continuous Operations
46.87%-38.63M
-443.34%-46.14M
-13.50%-27.08M
59.44%-12.3M
246.66%46.89M
46.29%-72.7M
140.41%13.44M
31.60%-23.86M
13.84%-30.31M
0.22%-31.97M
Minority interest income
Net income attributable to the parent company
46.87%-38.63M
-443.34%-46.14M
-13.50%-27.08M
59.44%-12.3M
246.66%46.89M
46.29%-72.7M
140.41%13.44M
31.60%-23.86M
13.84%-30.31M
0.22%-31.97M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
46.87%-38.63M
-443.34%-46.14M
-13.50%-27.08M
59.44%-12.3M
246.66%46.89M
46.29%-72.7M
140.41%13.44M
31.60%-23.86M
13.84%-30.31M
0.22%-31.97M
Basic earnings per share
53.06%-0.46
-422.20%-0.7039
-13.79%-0.33
65.12%-0.15
207.55%0.57
62.74%-0.98
137.67%0.2185
58.57%-0.29
39.44%-0.43
18.46%-0.53
Diluted earnings per share
53.06%-0.46
-422.20%-0.7039
-13.79%-0.33
65.12%-0.15
207.55%0.57
62.74%-0.98
137.67%0.2185
58.57%-0.29
39.44%-0.43
18.46%-0.53
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 63.54%123.67M-95.41%2.78M38.54%12.77M394.01%23.19M7,882.05%84.93M75.62M60.65M9.22M4.7M1.06M
Operating revenue 63.54%123.67M-95.41%2.78M38.54%12.77M394.01%23.19M7,882.05%84.93M--75.62M--60.65M--9.22M--4.7M--1.06M
Cost of revenue
Gross profit
Operating expense 13.49%177.88M10.19%52.5M27.98%45.74M3.78%38.75M13.56%40.89M9.37%156.73M36.66%47.64M-3.31%35.74M0.31%37.34M5.11%36.01M
Selling and administrative expenses 3.44%36.38M19.82%10.52M11.54%9.07M-12.79%8.1M-3.14%8.7M9.78%35.17M13.57%8.78M-6.17%8.13M13.96%9.28M19.74%8.99M
-General and administrative expense 3.44%36.38M19.82%10.52M11.54%9.07M-12.79%8.1M-3.14%8.7M9.78%35.17M13.57%8.78M-6.17%8.13M13.96%9.28M19.74%8.99M
Research and development costs 16.40%141.5M8.01%41.98M32.81%36.68M9.26%30.65M19.11%32.19M9.25%121.56M43.23%38.87M-2.44%27.62M-3.51%28.06M1.01%27.03M
Operating profit 33.17%-54.21M-482.31%-49.72M-24.31%-32.98M52.35%-15.55M226.01%44.04M43.40%-81.11M137.30%13M28.24%-26.53M12.30%-32.64M-2.01%-34.95M
Net non-operating interest income expense 22.49%12.94M42.16%3.69M-5.05%2.75M16.34%3.07M40.83%3.44M13.20%10.57M9.59%2.6M29.86%2.89M14.55%2.64M0.21%2.44M
Non-operating interest income 22.49%12.94M42.16%3.69M-5.05%2.75M16.34%3.07M40.83%3.44M13.20%10.57M9.59%2.6M29.86%2.89M14.55%2.64M0.21%2.44M
Other net income (expense) 270.91%1.54M-2,600.00%-50K81.05%-29K2,722.64%1.39M-62.58%232K140.12%416K100.26%2K-666.67%-153K23.19%-53K387.04%620K
Gain on sale of security 256.73%1.48M-2,600.00%-50K81.05%-29K2,722.64%1.39M-72.10%173K139.21%416K100.26%2K-666.67%-153K43.01%-53K387.04%620K
Special income (charges) --59K--0--0--0--59K--0--0--0--0--0
-Gain on sale of property,plant,equipment --59K--0--0--0--59K--0--0--0--0--0
Income before tax 43.36%-39.72M-395.34%-46.08M-27.20%-30.26M63.08%-11.1M249.62%47.71M48.06%-70.13M146.89%15.6M31.47%-23.79M14.09%-30.06M0.48%-31.89M
Income tax -142.68%-1.1M-97.27%59K-4,574.65%-3.18M375.79%1.2M890.36%822K660.36%2.57M9,936.36%2.16M-58.24%71K32.63%252K83K
Net income 46.87%-38.63M-443.34%-46.14M-13.50%-27.08M59.44%-12.3M246.66%46.89M46.29%-72.7M140.41%13.44M31.60%-23.86M13.84%-30.31M0.22%-31.97M
Net income continuous Operations 46.87%-38.63M-443.34%-46.14M-13.50%-27.08M59.44%-12.3M246.66%46.89M46.29%-72.7M140.41%13.44M31.60%-23.86M13.84%-30.31M0.22%-31.97M
Minority interest income
Net income attributable to the parent company 46.87%-38.63M-443.34%-46.14M-13.50%-27.08M59.44%-12.3M246.66%46.89M46.29%-72.7M140.41%13.44M31.60%-23.86M13.84%-30.31M0.22%-31.97M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 46.87%-38.63M-443.34%-46.14M-13.50%-27.08M59.44%-12.3M246.66%46.89M46.29%-72.7M140.41%13.44M31.60%-23.86M13.84%-30.31M0.22%-31.97M
Basic earnings per share 53.06%-0.46-422.20%-0.7039-13.79%-0.3365.12%-0.15207.55%0.5762.74%-0.98137.67%0.218558.57%-0.2939.44%-0.4318.46%-0.53
Diluted earnings per share 53.06%-0.46-422.20%-0.7039-13.79%-0.3365.12%-0.15207.55%0.5762.74%-0.98137.67%0.218558.57%-0.2939.44%-0.4318.46%-0.53
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 12 local time, U.S. Vice President Vance stated that negotiations between the United States and Iran failed to reach an agreement, Show More